Inactief instrument

Andere talen Oragenics Inc Nyse

Aandelen

Oragenics: Q1 Earnings Snapshot	15/05
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia	07/05
Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia	07/05
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	19/04
North American Morning Briefing : Big Banks Kick -2-	12/04
Oragenics, Inc. Files 10K and Provides Company Update	01/04
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03
Oragenics Announces Closing of Public Offering	04/03
Oragenics Announces Closing of Public Offering	01/03
Top Midday Decliners	28/02
Oragenics Announces Pricing of Public Offering	28/02
Oragenics Announces Proposed Public Offering	27/02
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	13/02
Oragenics, Inc. Announces Leadership Transition	12/02
Oragenics, Inc. Announces Leadership Transition	12/02
Oragenics, Inc. Announces CEO Changes	12/02

Geen resultaten voor deze zoekopdracht